Cargando…

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets

Detalles Bibliográficos
Autores principales:	Rybalkina, Irina G, Shimizu-Albergine, Masami, Rybalkin, Sergei D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363253/ http://dx.doi.org/10.1186/1471-2210-11-S1-P57

Ejemplares similares

Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX ouse model of Duchenne muscular dystrophy
por: Rybalkin, Sergei D, et al.
Publicado: (2013)

Activation of PDE10 and PDE11
por: Jäger, Ronald, et al.
Publicado: (2011)

Acute effects of phosphodiesterase 5 (PDE5) inhibition, ANP and NO on epididymal contractility are preserved despite chronic PDE5 exposure
por: Mietens, Andrea, et al.
Publicado: (2011)

A Yeast-Based Chemical Screen Identifies a PDE Inhibitor That Elevates Steroidogenesis in Mouse Leydig Cells via PDE8 and PDE4 Inhibition
por: Demirbas, Didem, et al.
Publicado: (2013)

cGMP kinase I, cardiac hypertrophy and PDE inhibition
por: Patrucco, Enrico, et al.
Publicado: (2011)

PDE3 is the major cGMP-PDE in adult mouse ventricular cardiomyocytes
por: Götz, Konrad R, et al.
Publicado: (2013)

Molecular targets for PDE inhibitor-mediated improvement of cardiac dysfunction in the mdx mouse?
por: Adamo, Candace M, et al.
Publicado: (2011)

PDE4 and PDE5 regulate cyclic nucleotide contents and relaxing effects on carbachol-induced contraction in the bovine abomasum
por: KANEDA, Takeharu, et al.
Publicado: (2014)

Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis
por: Egbert, Jeremy R., et al.
Publicado: (2016)

Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target
por: Long, Thavy, et al.
Publicado: (2017)

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases
por: Omar, Faisa, et al.
Publicado: (2019)

Comparative analysis of PDE10A isoforms
por: Russwurm, Corina, et al.
Publicado: (2011)

Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses
por: O'Brien, Jennifer J., et al.
Publicado: (2019)

PDE expression and contractility of seminiferous tubules of the human testis
por: Feuerstacke, Caroline, et al.
Publicado: (2011)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

PDE2, a component of the NO/cGMP signalling in the hippocampus
por: Schönle, Isabel, et al.
Publicado: (2011)

Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation
por: Dolce, Bernardo, et al.
Publicado: (2020)

Phosphodiesterase 9 (PDE9) regulates bovine tracheal smooth muscle relaxation
por: TAJIMA, Tsuyoshi, et al.
Publicado: (2018)

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
por: Alexander, M S, et al.
Publicado: (2016)

Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra
por: Rahardjo, Harrina E, et al.
Publicado: (2021)

Cyclic nucleotide phosphodiesterases – 40 years of progress
por: Beavo, Joseph A, et al.
Publicado: (2009)

Identification of cytosolic phosphodiesterases in the erythrocyte: A possible role for PDE5
por: Adderley, Shaquria P., et al.
Publicado: (2011)

Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells
por: Dong, Hongli, et al.
Publicado: (2013)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
por: Basole, Chaitali P., et al.
Publicado: (2022)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

PDE-Mediated Cyclic Nucleotide Compartmentation in Vascular Smooth Muscle Cells: From Basic to a Clinical Perspective
por: Lorigo, Margarida, et al.
Publicado: (2021)

Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor
por: Keravis, Thérèse, et al.
Publicado: (2012)

Differential effects of selective PDE5 inhibitors in rat cerebral arteries in vitro and in vivo
por: Kruuse, Christina, et al.
Publicado: (2009)

Experimental evidence that a combination of sGC stimulator BAY 60-4552 and PDE5 inhibitor vardenafil could salvage ED-patients with insufficient response to PDE5 inhibitors after cavernous nerve injury
por: Oudot, Alexandra, et al.
Publicado: (2011)

The neuronal PDE2A3 splice variant is targeted to membranes via dual acylation
por: Russwurm, Corina, et al.
Publicado: (2009)

Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
por: Loeb, Stacy, et al.
Publicado: (2017)

Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis
por: Totani, Licia, et al.
Publicado: (2021)

Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)

Phosphodiesterase 1b (PDE1B) Regulates Spatial and Contextual Memory in Hippocampus
por: McQuown, Susan, et al.
Publicado: (2019)

Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease
por: Cesarini, Valeriana, et al.
Publicado: (2020)

Arterial methemoglobin level predicts therapeutic effectiveness of the PDE5 inhibitors in patients with in idiopathic pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2011)

AB081. Effects of combination therapy of Tamoxifen, L-carnitine and daily PDE5 inhibitors in the Peyronie’s disease
por: Kang, Jae Il, et al.
Publicado: (2016)

S31. ENHANCEMENT OF SYNAPTIC PLASTICITY BY COMBINATION OF PDE2 AND PDE9 INHIBITION PRESUMABLY VIA PRE- AND POST-SYNAPTIC MECHANISMS
por: Rosenbrock, Holger, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_df7095pd6k99nrfj6pf9t8um4r